Water → HCID 44411557, 화합물

반응식

C[O:2][C:3](=[O:37])[CH2:4][O:5][C:6]1[CH:11]=[CH:10][C:9]([O:12][CH2:13][C:14]2[N:19]=[C:18]([C:20]3[CH:25]=[CH:24][C:23]([O:26][CH3:27])=[CH:22][CH:21]=3)[CH:17]=[C:16]([C:28]3[CH:33]=[CH:32][C:31]([O:34][CH3:35])=[CH:30][CH:29]=3)[N:15]=2)=[CH:8][C:7]=1[CH3:36].O.[OH-].[Li+].O>O1CCOCC1>[CH3:35][O:34][C:31]1[CH:30]=[CH:29][C:28]([C:16]2[CH:17]=[C:18]([C:20]3[CH:21]=[CH:22][C:23]([O:26][CH3:27])=[CH:24][CH:25]=3)[N:19]=[C:14]([CH2:13][O:12][C:9]3[CH:10]=[CH:11][C:6]([O:5][CH2:4][C:3]([OH:37])=[O:2])=[C:7]([CH3:36])[CH:8]=3)[N:15]=2)=[CH:33][CH:32]=1

참가 물질

실험 절차

{4-[4,6-Bis-(4-methoxy-phenyl)-pyrimidin-2-ylmethoxy]-2-methyl-phenoxy}-acetic acid methyl ester 25 (0.14 g, 0.28 mmol) from Step D above is dissolved in dioxane (2 mL). Solid lithium hydroxide monohydrate (80 mg, 2.0 mmol) is added, followed by water (0.2 mL). After stirring at room temperature for 5 hours, the mixture is concentrated to dryness. Purification by reversed-phase HPLC afforded {4-[4,6-Bis-(4-methoxy-phenyl)-pyrimidin-2-ylmethoxy]-2-methyl-phenoxy}-acetic acid B1 as a solid. MS calculated for C28H27N2O6 (M+H+) 487.18. found 487.2.